Projects
Collaborative Projects
The research consortium, which received approximately two million euros in funding from the Bavarian Research Foundation, was launched in May 2023. It is working on cell therapies for oncology and infectious diseases. Prof. Sebastian Kobold serves as the consortium’s spokesperson.
The foundation is funding a collaborative project at the center focused on the safety of CAR-T cell therapy. In addition to Hematology, the departments involved include Clinical Pharmacology, Neurology, Neurosurgery, Nuclear Medicine, Radiology, Neuroradiology, Pathology, Dermatology, the Department of Pediatrics, and Psycho-Oncology.
With its first round of funding, the M1 – Munich Medicine Alliance is strengthening cutting-edge translational research across institutional boundaries. As part of the “Innovations for Patients” program, the Alliance is funding seven research projects with a total of approximately 7.45 million euros to accelerate the translation of scientific findings into patient care.
The funded projects address diseases with a high disease burden and significant relevance for patients—including cancer, cardiovascular diseases, neurodegenerative diseases, and vision loss. At the same time, this funding initiative fosters new, cross-institutional collaborations in Munich.
Our funded project:
CarIMMUN: Boosting T-Cell-Based Immunotherapy in Relapsed/Refractory Multiple Myeloma via Carfilzomib-Induced Antigen Enhancement: Prof. Florian Bassermann, TUM School of Medicine / PD Dr. Judith S. Hecker, TUM School of Medicine / Prof. Marion Subklewe, LMU School of Medicine / Prof. Sebastian Theurich, LMU School of Medicine
Since 2024, the research group has been developing new gene therapies for inherited and acquired retinal diseases, including those that have been difficult or impossible to treat until now. The gene delivery vehicles currently in use, which are based on adeno-associated viruses, cannot deliver larger genes and cannot reach some retinal cells. This is where the group comes in. The group’s spokesperson is Prof. Stylianos Michalakis. In addition to LMU and LMU University Hospital Munich, the University of Zurich, the Technical University of Munich, and Helmholtz Munich are also involved.
The Collaborative Research Center LETSIMMUN (Lymphocyte Engineering for Therapeutic Synthetic Immunity) has been funded by the German Research Foundation (DFG) since 2021. Research groups in Munich and Würzburg are developing methods to specifically modify immune cells to treat cancer, infections, and autoimmune diseases. The spokesperson is Prof. Dirk Busch from the Technical University of Munich; the LMU spokesperson is Prof. Marion Subklewe. Together with Prof. Sebastian Kobold, she leads a subproject that equips CAR-T cells with disease-specific chemokine receptors. Other subprojects are led by Prof. Louisa von Baumgarten and Prof. Tobias Feuchtinger.
